Drug Type Radiolabeled antibody, Therapeutic radiopharmaceuticals |
Synonyms 90 Y-FF-21101, 90Y-FF-21101, 90Y-PPMX-T002 + [3] |
Target |
Mechanism CDH3 inhibitors(Cadherin 3 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced cancer | Phase 1 | US | 01 Jan 2016 | |
Advanced Malignant Solid Neoplasm | Phase 1 | US | 01 Jan 2016 | |
Bile Duct Neoplasms | Phase 1 | US | 01 Jan 2016 | |
Colorectal Cancer | Phase 1 | US | 01 Jan 2016 | |
Fallopian Tube Carcinoma | Phase 1 | US | 01 Jan 2016 | |
Gallbladder Carcinoma | Phase 1 | US | 01 Jan 2016 | |
Pancreatic Cancer | Phase 1 | US | 01 Jan 2016 | |
Squamous Cell Carcinoma of Head and Neck | Phase 1 | US | 01 Jan 2016 | |
Triple Negative Breast Cancer | Phase 1 | US | 01 Jan 2016 | |
Solid tumor | Phase 1 | JP | - |
AACR2018 Manual | Not Applicable | 14 | qcrwvxzvjn(rtvteitxer) = fwapgazltl dswjmrbpfh (kpuqqeybvm ) View more | Positive | 01 Jul 2018 |